JP2024038024A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024038024A5 JP2024038024A5 JP2023216113A JP2023216113A JP2024038024A5 JP 2024038024 A5 JP2024038024 A5 JP 2024038024A5 JP 2023216113 A JP2023216113 A JP 2023216113A JP 2023216113 A JP2023216113 A JP 2023216113A JP 2024038024 A5 JP2024038024 A5 JP 2024038024A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- culture medium
- cell culture
- population
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 46
- 210000004027 cell Anatomy 0.000 claims 41
- 239000006143 cell culture medium Substances 0.000 claims 40
- 101001128732 Homo sapiens Nucleoside diphosphate kinase 7 Proteins 0.000 claims 16
- 102100032115 Nucleoside diphosphate kinase 7 Human genes 0.000 claims 16
- 210000000130 stem cell Anatomy 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 4
- 101000979629 Homo sapiens Nucleoside diphosphate kinase A Proteins 0.000 claims 4
- 101000979623 Homo sapiens Nucleoside diphosphate kinase B Proteins 0.000 claims 4
- 102100023252 Nucleoside diphosphate kinase A Human genes 0.000 claims 4
- 102100023258 Nucleoside diphosphate kinase B Human genes 0.000 claims 4
- 108091000080 Phosphotransferase Proteins 0.000 claims 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 4
- 239000012190 activator Substances 0.000 claims 4
- 239000001177 diphosphate Substances 0.000 claims 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 4
- 235000011180 diphosphates Nutrition 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 230000037361 pathway Effects 0.000 claims 4
- 102000020233 phosphotransferase Human genes 0.000 claims 4
- 102000034285 signal transducing proteins Human genes 0.000 claims 4
- 108091006024 signal transducing proteins Proteins 0.000 claims 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 4
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 claims 3
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 claims 3
- 102100020677 Krueppel-like factor 4 Human genes 0.000 claims 3
- 102000038030 PI3Ks Human genes 0.000 claims 3
- 108091007960 PI3Ks Proteins 0.000 claims 3
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 claims 3
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 claims 3
- 102100024270 Transcription factor SOX-2 Human genes 0.000 claims 3
- 239000003590 rho kinase inhibitor Substances 0.000 claims 3
- 210000001082 somatic cell Anatomy 0.000 claims 3
- 230000002463 transducing effect Effects 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 239000002211 L-ascorbic acid Substances 0.000 claims 2
- 235000000069 L-ascorbic acid Nutrition 0.000 claims 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims 2
- -1 NANOG Proteins 0.000 claims 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims 2
- 102000004338 Transferrin Human genes 0.000 claims 2
- 108090000901 Transferrin Proteins 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 229960005070 ascorbic acid Drugs 0.000 claims 2
- 239000003797 essential amino acid Substances 0.000 claims 2
- 235000020776 essential amino acid Nutrition 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 2
- 102000000568 rho-Associated Kinases Human genes 0.000 claims 2
- 108010041788 rho-Associated Kinases Proteins 0.000 claims 2
- 229910052711 selenium Inorganic materials 0.000 claims 2
- 239000011669 selenium Substances 0.000 claims 2
- 239000012581 transferrin Substances 0.000 claims 2
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 claims 1
- 102100025460 Protein lin-28 homolog A Human genes 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 210000002459 blastocyst Anatomy 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (30)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548199P | 2011-10-17 | 2011-10-17 | |
| US61/548,199 | 2011-10-17 | ||
| US201261618578P | 2012-03-30 | 2012-03-30 | |
| US61/618,578 | 2012-03-30 | ||
| US201261622422P | 2012-04-10 | 2012-04-10 | |
| US61/622,422 | 2012-04-10 | ||
| USPCT/US2012/036975 | 2012-05-08 | ||
| PCT/US2012/036975 WO2012154759A2 (en) | 2011-05-09 | 2012-05-08 | Genetically engineered growth factor variants |
| US201261671588P | 2012-07-13 | 2012-07-13 | |
| US201261671558P | 2012-07-13 | 2012-07-13 | |
| US61/671,558 | 2012-07-13 | ||
| US61/671,588 | 2012-07-13 | ||
| US201261673617P | 2012-07-19 | 2012-07-19 | |
| US61/673,617 | 2012-07-19 | ||
| US201261675264P | 2012-07-24 | 2012-07-24 | |
| US201261675292P | 2012-07-24 | 2012-07-24 | |
| US61/675,292 | 2012-07-24 | ||
| US61/675,264 | 2012-07-24 | ||
| US201261677442P | 2012-07-30 | 2012-07-30 | |
| US61/677,442 | 2012-07-30 | ||
| US201261679021P | 2012-08-02 | 2012-08-02 | |
| US61/679,021 | 2012-08-02 | ||
| US201261683155P | 2012-08-14 | 2012-08-14 | |
| US61/683,155 | 2012-08-14 | ||
| US201261684654P | 2012-08-17 | 2012-08-17 | |
| US61/684,654 | 2012-08-17 | ||
| US201261693712P | 2012-08-27 | 2012-08-27 | |
| US61/693,712 | 2012-08-27 | ||
| JP2016231442A JP2017074054A (ja) | 2011-10-17 | 2016-11-29 | 幹細胞の増殖及び誘導用の培地 |
| JP2021211485A JP2022046658A (ja) | 2011-10-17 | 2021-12-24 | 幹細胞の増殖及び誘導用の培地 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021211485A Division JP2022046658A (ja) | 2011-10-17 | 2021-12-24 | 幹細胞の増殖及び誘導用の培地 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024038024A JP2024038024A (ja) | 2024-03-19 |
| JP2024038024A5 true JP2024038024A5 (https=) | 2024-05-21 |
Family
ID=48141618
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537191A Expired - Fee Related JP6466170B2 (ja) | 2011-10-17 | 2012-10-17 | 幹細胞の増殖及び誘導用の培地 |
| JP2016231442A Pending JP2017074054A (ja) | 2011-10-17 | 2016-11-29 | 幹細胞の増殖及び誘導用の培地 |
| JP2020122592A Pending JP2020182483A (ja) | 2011-10-17 | 2020-07-17 | 幹細胞の増殖及び誘導用の培地 |
| JP2021211485A Pending JP2022046658A (ja) | 2011-10-17 | 2021-12-24 | 幹細胞の増殖及び誘導用の培地 |
| JP2023216113A Pending JP2024038024A (ja) | 2011-10-17 | 2023-12-21 | 幹細胞の増殖及び誘導用の培地 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537191A Expired - Fee Related JP6466170B2 (ja) | 2011-10-17 | 2012-10-17 | 幹細胞の増殖及び誘導用の培地 |
| JP2016231442A Pending JP2017074054A (ja) | 2011-10-17 | 2016-11-29 | 幹細胞の増殖及び誘導用の培地 |
| JP2020122592A Pending JP2020182483A (ja) | 2011-10-17 | 2020-07-17 | 幹細胞の増殖及び誘導用の培地 |
| JP2021211485A Pending JP2022046658A (ja) | 2011-10-17 | 2021-12-24 | 幹細胞の増殖及び誘導用の培地 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11591565B2 (https=) |
| EP (1) | EP2768945B1 (https=) |
| JP (5) | JP6466170B2 (https=) |
| CN (2) | CN103998598A (https=) |
| AU (1) | AU2012326137B2 (https=) |
| CA (1) | CA2852244C (https=) |
| IL (1) | IL232107B (https=) |
| WO (1) | WO2013059373A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2686418A4 (en) | 2011-03-17 | 2015-04-22 | Minerva Biotechnologies Corp | METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS |
| EP2768945B1 (en) | 2011-10-17 | 2022-01-05 | Minerva Biotechnologies Corporation | Media for stem cell proliferation and induction |
| JP6748430B2 (ja) * | 2012-07-13 | 2020-09-02 | ミネルバ バイオテクノロジーズ コーポレーション | より未分化状態への細胞の誘導方法 |
| TWI659210B (zh) * | 2013-08-12 | 2019-05-11 | Minerva Biotechnologies Corporation | 加強腫瘤生長的方法 |
| CN106414726A (zh) * | 2014-04-07 | 2017-02-15 | 米纳瓦生物技术公司 | 抗nme抗体 |
| CA2976089C (en) | 2015-02-10 | 2026-01-13 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies |
| AU2016287603A1 (en) * | 2015-07-01 | 2018-01-25 | Minerva Biotechnologies Corporation | Method of stem cell-based organ and tissue generation |
| JP2019515643A (ja) * | 2015-09-23 | 2019-06-13 | ミネルバ バイオテクノロジーズ コーポレーション | 幹細胞分化剤のスクリーニング方法 |
| US20190194621A1 (en) * | 2016-09-08 | 2019-06-27 | Kyowa Hakko Bio Co., Ltd. | Medium for culturing stem cells, method for culturing stem cells, growth promoter for stem cells, and cell composition and method for producing same |
| JP2020500031A (ja) * | 2016-10-11 | 2020-01-09 | ミネルバ バイオテクノロジーズ コーポレーション | ヒト化抗ｍｕｃ１＊抗体及び開裂酵素の使用 |
| KR102121042B1 (ko) * | 2017-12-06 | 2020-06-09 | 이정복 | 조류의 에그로부터 분리한 세포인 배반엽 전분화능세포, 신경줄기세포, 배아섬유아세포 컨디션드 배지를 유효성분으로 하는 세포 증식, 피부재생 및 주름 개선용 배지 조성물 |
| EP3920693A4 (en) | 2019-02-04 | 2022-10-05 | Minerva Biotechnologies Corporation | ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS |
| JP2022548776A (ja) * | 2019-09-19 | 2022-11-21 | ノースウェスタン ユニバーシティ | ヒト人工多能性幹細胞のための費用効果の高い培地およびプロトコル |
| CN116367857A (zh) | 2020-06-08 | 2023-06-30 | 米纳瓦生物技术公司 | 抗nme抗体及治疗癌症或癌症转移的方法 |
| KR20230028796A (ko) | 2020-06-26 | 2023-03-02 | 미네르바 바이오테크놀로지 코포레이션 | 항-nme 항체 및 암 또는 암 전이의 치료 방법 |
| JP7581015B2 (ja) | 2020-10-30 | 2024-11-12 | 株式会社小松製作所 | データ送信システム、作業機械、および作業機械のデータ送信方法 |
| KR20250009592A (ko) | 2022-04-12 | 2025-01-17 | 미네르바 바이오테크놀로지 코포레이션 | 항-가변 muc1* 항체 및 그의 용도 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| EP0804249A2 (en) | 1994-03-15 | 1997-11-05 | Brown University Research Foundation | Polymeric gene delivery system |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| EP2322929B1 (en) | 2000-11-27 | 2016-04-06 | Minerva Biotechnologies Corporation | diagnostics, drug screening and treatment for cancer |
| JP2005507876A (ja) | 2001-09-05 | 2005-03-24 | ミナーバ バイオテクノロジーズ コーポレイション | 癌を治療する組成物および方法 |
| EP1375661A1 (en) | 2002-06-17 | 2004-01-02 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | The role of the N-myc - nm23H1/nm23H2 - cdc42 pathway in proliferation, differentiation and treatment of cancer |
| CA2537263C (en) | 2002-11-27 | 2017-05-30 | Minerva Biotechnologies Corporation | Techniques and compositions for the diagnosis and treatment of cancer (muc1) |
| GB0328245D0 (en) * | 2003-12-05 | 2004-01-07 | Univ Birmingham | Therapeutic use of biological cells |
| US20080064680A1 (en) | 2004-09-14 | 2008-03-13 | Bamdad Cynthia C | Methods for Diagnosis and Treatment of Cancer |
| CA2610292C (en) * | 2005-03-30 | 2015-06-02 | Minerva Biotechnologies Corporation | Proliferation of muc1 expressing cells |
| CA2650841A1 (en) | 2005-06-06 | 2006-12-14 | Suomen Punainen Risti, Veripalvelu | Method of profiling a cell population |
| CN101273060A (zh) | 2005-06-24 | 2008-09-24 | 美国政府（由卫生和人类服务部、国立卫生研究院的部长所代表） | 通过靶向肿瘤坏死因子受体的前配体装配域(plad)来缓解炎性关节炎 |
| JP2008099662A (ja) | 2006-09-22 | 2008-05-01 | Institute Of Physical & Chemical Research | 幹細胞の培養方法 |
| WO2008067065A2 (en) | 2006-10-19 | 2008-06-05 | Shiv Srivastava | Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers |
| WO2008070082A2 (en) | 2006-12-04 | 2008-06-12 | The Johns Hopkins University | Stem-progenitor cell specific micro-ribonucleic acids and uses thereof |
| CN101652469B (zh) * | 2006-12-06 | 2014-04-16 | 米纳瓦生物技术公司 | 用于鉴定和操作细胞的方法 |
| WO2009012173A2 (en) | 2007-07-13 | 2009-01-22 | Dharmacon, Inc. | Enhanced biotherapeutic production using inhibitory rna |
| WO2009075787A1 (en) | 2007-12-05 | 2009-06-18 | The Johns Hopkins University | Compositions and methods of treating neoplasia |
| US20090148535A1 (en) * | 2007-12-06 | 2009-06-11 | Minerva Biotechnologies Corporation | Method for treating cancer using interference rna |
| US20100278788A1 (en) * | 2008-01-11 | 2010-11-04 | Bone Therapeutics, S.A. | Osteogenic Differentiation Of Bone Marrow Stem Cells And Mesenchymal Stem Cells Using A Combination Of Growth Factors |
| US20110014164A1 (en) * | 2008-02-15 | 2011-01-20 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
| JP5464443B2 (ja) | 2008-03-31 | 2014-04-09 | オリエンタル酵母工業株式会社 | 多能性幹細胞を増殖させる方法 |
| EP3279314A1 (en) | 2008-06-04 | 2018-02-07 | Cellular Dynamics International, Inc. | Methods for the production of ips cells using non-viral approach |
| US9144584B2 (en) | 2008-06-11 | 2015-09-29 | Cell4Vet Corporation | Adipose tissue-derived stem cells for veterinary use |
| WO2010042891A2 (en) * | 2008-10-09 | 2010-04-15 | Minerva Biotechnologies Corporation | Method for inducing pluripotency in cells |
| WO2010042981A1 (en) | 2008-10-14 | 2010-04-22 | Shaun Joseph Cunningham | Photo-voltaic device |
| CA2741090C (en) | 2008-10-24 | 2018-10-16 | Wisconsin Alumni Research Foundation | Pluripotent stem cells obtained by non-viral reprogramming |
| KR20110134939A (ko) | 2009-04-03 | 2011-12-15 | 더 맥클린 하스피털 코퍼레이션 | 유도된 다능성 줄기 세포 |
| US20120115225A1 (en) | 2009-04-23 | 2012-05-10 | Xu C W | Reprogramming of somatic cells with purified proteins |
| SG176801A1 (en) * | 2009-06-11 | 2012-01-30 | Minerva Biotechnologies Corp | Methods for culturing stem and progenitor cells |
| EP3633025B1 (en) * | 2009-11-12 | 2022-09-14 | Technion Research & Development Foundation Ltd. | Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state |
| EP3228629A1 (en) * | 2010-06-16 | 2017-10-11 | Minerva Biotechnologies Corporation | Reprogramming cancer cells |
| CN103189511B (zh) | 2010-07-12 | 2016-10-12 | 国立大学法人鸟取大学 | 利用siRNA导入的新型hiPSC制作法 |
| WO2012051515A2 (en) | 2010-10-14 | 2012-04-19 | University Of Central Florida Research Foundation, Inc. | Cardiac induced pluripotent stem cells and methods of use in repair and regeneration of myocardium |
| EP2768945B1 (en) | 2011-10-17 | 2022-01-05 | Minerva Biotechnologies Corporation | Media for stem cell proliferation and induction |
| JP6748430B2 (ja) | 2012-07-13 | 2020-09-02 | ミネルバ バイオテクノロジーズ コーポレーション | より未分化状態への細胞の誘導方法 |
| CN111849874A (zh) | 2012-07-24 | 2020-10-30 | 米纳瓦生物技术公司 | Nme变体物种表达和抑制 |
-
2012
- 2012-10-17 EP EP12841648.4A patent/EP2768945B1/en active Active
- 2012-10-17 AU AU2012326137A patent/AU2012326137B2/en active Active
- 2012-10-17 WO PCT/US2012/060684 patent/WO2013059373A2/en not_active Ceased
- 2012-10-17 JP JP2014537191A patent/JP6466170B2/ja not_active Expired - Fee Related
- 2012-10-17 CN CN201280062509.8A patent/CN103998598A/zh active Pending
- 2012-10-17 CN CN201811288611.5A patent/CN109456932A/zh active Pending
- 2012-10-17 CA CA2852244A patent/CA2852244C/en active Active
-
2014
- 2014-04-13 IL IL232107A patent/IL232107B/en active IP Right Grant
- 2014-04-16 US US14/254,749 patent/US11591565B2/en active Active
-
2016
- 2016-11-29 JP JP2016231442A patent/JP2017074054A/ja active Pending
-
2020
- 2020-07-17 JP JP2020122592A patent/JP2020182483A/ja active Pending
-
2021
- 2021-12-24 JP JP2021211485A patent/JP2022046658A/ja active Pending
-
2023
- 2023-01-12 US US18/153,974 patent/US11976295B2/en active Active
- 2023-12-21 JP JP2023216113A patent/JP2024038024A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024038024A5 (https=) | ||
| US20230165908A1 (en) | Cryopreserved endocrine cells that express chromogranin a | |
| JP7548538B2 (ja) | 多能性幹細胞から機能的心筋へと直接分化させる方法 | |
| CN110662832B (zh) | 由间介中胚层细胞分化诱导肾祖细胞的方法和由多能干细胞分化诱导肾祖细胞的方法 | |
| US8609417B2 (en) | Methods and compositions for stem cell cultures | |
| AU2026201562A1 (en) | Cell compositions derived from dedifferentiated reprogrammed cells | |
| EP2383333B1 (en) | Method for producing polarized retinal progenitor cells from pluripotent stem cells and their differentiation into retinal pigment epithelium cells | |
| CN104520424B (zh) | 使用合成的信使rna无饲养细胞地衍生人类诱导性多能干细胞 | |
| Morali et al. | IGF-II promotes mesoderm formation | |
| JP2014530025A5 (https=) | ||
| JP6039551B2 (ja) | 透析された血清を有する心筋細胞培地 | |
| CN102144027B (zh) | 生产多能干细胞的方法 | |
| US20190264171A1 (en) | Differentiation of pluripotent stem cells into corneal cells | |
| Wang et al. | Generation of electrophysiologically functional cardiomyocytes from mouse induced pluripotent stem cells | |
| KR20240125943A (ko) | 신경능 세포의 배양 방법 및 제조 방법 | |
| TWI698526B (zh) | 利用合成之信使ｒｎａ進行之人類誘導型多能幹細胞之無餵養細胞衍化（ｄｅｒｉｖａｔｉｏｎ） | |
| KR101647030B1 (ko) | 미토푸신 억제제를 포함하는, 세포 리프로그래밍 촉진용 조성물 및 이의 용도 | |
| JP5892554B2 (ja) | 未分化状態の制御剤およびその用途 | |
| Georgescu et al. | Downregulation of polo-like kinase correlates with loss of proliferative ability of cardiac myocytes | |
| US8895301B2 (en) | Exogenous Pax6 nucleic acid expression in primate neural stem cells maintains proliferation without differentiation | |
| JP7698309B2 (ja) | 多能性幹細胞からの造血細胞の製造法 | |
| JP7851919B2 (ja) | ラフト培養物及びその作製方法 | |
| CN113811605B (zh) | 从人多能干细胞获得眼野祖细胞的方法 | |
| US20240352412A1 (en) | Methods and systems for extended culture of human blastoids to post-implantation stages on 3d matrices | |
| Wong et al. | Molecular mechanism involved in the maintenance of pluripotent stem cells |